Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 24 of 24 entries
View as:

Liquid Biopsy: Intercepting Mutational Trajectories of HER2 (Human Epidermal Growth Factor Receptor 2) Breast Cancer (GIM21 Trial)

Phase: N/A Priority: Normal
NCT ID: NCT05735392 Org: User:
Start: 11/07/18 End: 01/12/22 Due: 01/12/23

Prospective Observational Study of Adjuvant Hormone Treatment in Estrogen-receptor Positive Premenopausal Early Breast Cancer Patients

Phase: N/A Priority: Normal
NCT ID: NCT05730647 Org: User:
Start: 10/24/19 End: 07/31/32 Due: 07/31/33

FEC With G-CSF Support Followed by Ixabepilone With G-CSF Support as Neoadjuvant Chemotherapy in BC

Phase: N/A Priority: Normal
NCT ID: NCT00751868 Org: User:
Start: 09/30/08 End: 07/31/11 Due: 07/31/12

Axitinib Intensification Plus Nivolumab or Nivolumab Alone After Nivolumab Plus Ipilimumab in mRCC Patients

Phase: N/A Priority: Normal
NCT ID: NCT05817903 Org: User:
Start: 04/18/23 End: 04/01/27 Due: 04/01/28

Dexamethasone-sparing Approach Including NEPA Against Emesis Caused by Cisplatin

Phase: N/A Priority: Normal
NCT ID: NCT04201769 Org: User:
Start: 11/25/16 End: 04/30/20 Due: 04/30/21

NEPA to Prevent Chemotherapy Induced Nausea and Vomiting in Patients With Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03862144 Org: User:
Start: 05/12/16 End: 04/03/17 Due: 04/03/18

Avelumab Plus Intermittent Axitinib in Previously Untreated Patients With Metastatic Renal Cell Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT04698213 Org: User:
Start: 10/07/20 End: 10/31/24 Due: 10/31/25

Atezolizumab Plus CArboplatin Plus Nab-paclitaxel

Phase: N/A Priority: Normal
NCT ID: NCT05266937 Org: User:
Start: 07/03/20 End: 07/03/24 Due: 07/03/25

Safety and QoL of Trastuzumab With Lapatinib or Chemiotherapy in MBC and HER2+ Patients Refractory to Anti HER2 Therapies

Phase: N/A Priority: Normal
NCT ID: NCT02238509 Org: User:
Start: 11/30/14 End: 10/31/17 Due: 10/31/18

Safety and Efficacy Study of Eribulin in Combination With Bevacizumab for Second-line Treatment HER2- MBC Patients

Phase: N/A Priority: Normal
NCT ID: NCT02175446 Org: User:
Start: 09/30/14 End: 12/31/17 Due: 12/31/18

Efficacy of PErioperative PEmbrolizumab Treatment in Patients With Resectable Metastases From Kidney Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05578664 Org: User:
Start: 03/14/23 End: 10/31/25 Due: 10/31/26

Isoquercetin as an Adjunct Therapy in Patients With Kidney Cancer Receiving First-line Sunitinib: a Phase I/II Trial

Phase: N/A Priority: Normal
NCT ID: NCT02446795 Org: User:
Start: 11/30/16 End: 12/31/17 Due: 12/31/18

CABAzitaxel With or Without Prednisone in Patients With Metastatic CAstration REsistant Prostate Cancer Progressed During or After a Previous Docetaxel-based Chemotherapy

Phase: N/A Priority: Normal
NCT ID: NCT03356912 Org: User:
Start: 11/22/17 End: 05/04/21 Due: 05/04/22

Second Line ERIbulin Followed by CApecitabine or the Reverse Sequence in HER2-negative Metastatic Breast Cancer Patients

Phase: N/A Priority: Normal
NCT ID: NCT05833919 Org: User:
Start: 07/30/18 End: 07/31/23 Due: 07/31/24

Avelumab as Single Agent in Metastatic or Locally Advanced Urothelial Cancer in Patients Unfit for Cisplatin. The ARIES Study

Phase: N/A Priority: Normal
NCT ID: NCT03891238 Org: User:
Start: 02/06/19 End: 09/15/21 Due: 09/15/22

Measure of Outcomes in Patients With Advanced Ovarian Cancer According to Homologous Recombination Status and Matched Therapies in a Real-world Scenario

Phase: N/A Priority: Normal
NCT ID: NCT06836219 Org: User:
Start: 09/13/24 End: 01/31/29 Due: 01/31/30

Overcoming Endocrine Resistance in Metastatic Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02394496 Org: User:
Start: 11/30/07 End: 01/31/17 Due: 01/31/18

Fulvestrant as Maintenance Therapy After First-line Chemotherapy in HER2 - Postmenopausal MBC Patients

Phase: N/A Priority: Normal
NCT ID: NCT02383030 Org: User:
Start: 11/30/15 End: 12/31/17 Due: 12/31/18

Fulvestrant and EVerolimus Plus EXemestane in Metastatic Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02404051 Org: User:
Start: 12/31/15 End: 01/31/19 Due: 01/31/20

Evaluation of Medical Treatments in MBC Patients According Biological Subtype and Line of Treatments

Phase: N/A Priority: Normal
NCT ID: NCT02284581 Org: User:
Start: 11/30/15 End: 12/31/25 Due: 12/31/26

Observational Study of Effectiveness and Safety of Trastuzumab Emtansine (T-DM1) in HER2-positive Breast Cancer Patients With Residual Invasive Disease Following Neoadjuvant Chemotherapy and Anti-HER2 Target Therapy

Phase: N/A Priority: Normal
NCT ID: NCT05754502 Org: User:
Start: 07/27/21 End: 05/02/25 Due: 05/02/26

Observation of Medical Treatments in MBC HER2-negative Patients

Phase: N/A Priority: Normal
NCT ID: NCT02365831 Org: User:
Start: 05/31/15 End: 12/31/17 Due: 12/31/18

Palbociclib Plus Fulvestrant in Women With Hormone Receptor Positive and Human Epidermal Growth Factor Receptor Type 2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated With a CDK4/6 Inhibitor in Combination With Hormonal Therapy

Phase: N/A Priority: Normal
NCT ID: NCT04318223 Org: User:
Start: 07/16/19 End: 07/31/23 Due: 07/31/24

"Observational, Retrospective and Prospective, Non-interventional, Multicentre on the Use of Genomic Testing in the Management of Early Stage HR+/HER2- Breast Cancer"

Phase: N/A Priority: Normal
NCT ID: NCT06871501 Org: User:
Start: 03/31/25 End: 11/30/26 Due: 11/30/27